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ABSTRACT 
 
Luciana E. Leopold: Development of Real-Time PCR Assays for the Quantitative 
Detection of Herpesviruses 
 (Under the direction of Dirk P. Dittmer, Ph.D.) 
 
Kaposis’s sarcoma-associated Herpesvirus (KSHV) and Human Epstein-Barr 
virus (EBV) are gamma herpesviruses that can cause serious complications in immuno-
compromised patients.  Quantitative detection is critical not only as a diagnostic tool in 
patients, but also as a method for basic herpesvirology research.  Here the development 
and validation of four real-time PCR assays to quantify viral load of KSHV and EBV in 
samples is described.  The assays are: individual viral load assays for KSHV and EBV, 
and high-throughput viral load screens for KSHV and EBV. The assays were developed 
for validation of animal models, drug response studies, basic virology research and 
medical diagnostics. The data indicate that these are accurate, consistent, and cost-
effective assays for the detection of KSHV and EBV infection in various kinds of 
samples. 
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I. INTRODUCTION 
 
 Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 (HHV-
8) and Epstein-Barr virus (EBV) or human herpesvirus 4 (HHV-4) are both members of 
the viral subfamily of gamma herpesviruses.  KSHV is an ongogenic herpesvirus known 
to cause Kaposi’s sarcoma (KS) (2,6),and is associated with multicentric Castleman’s 
disease (MCD) (14) and primary effusion lymphoma (PEL) (5).  Like KSHV, EBV has, 
aside from causing infectious mononucleosis, been shown to be oncogenic and involved 
in the development of various malignancies, i.e. African Burkitt’s lymphoma, B-cell 
lymphoma, nasopharyngeal carcinoma, and in some cases of Hodgkin’s disease and 
gastric cancer. (19) Both KSHV and EBV have their most severe impacts on immuno-
compromised patients, particularly AIDS patients, as it is believed that the host response 
is weakened in these patients and reactivation of the virus can occur, leading to lytic 
replication and malignancy. Early diagnosis of reactivation of these viruses after initial 
latent infection is key to disease management so that anti-viral therapy can begin as soon 
as possible.  Accurate, quantitative methods are needed to detect the viruses.  Aside from 
the obvious clinical relevance that such quantitative assays would have, they could also 
broadly apply to basic research into these viruses. 
 Amplification of viral DNA by polymerase chain reaction (PCR) is an effective 
method for detecting viral DNA.  Qualitative PCR assays have in the past been very 
useful for screening samples for the presence of viral DNA (11, 27).  For applications as 
those mentioned above – detecting the difference between lack of infection, latent 
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infection, and reactivated infection – quantitative analysis must be used.  Quantitative 
real-time PCR can be utilized to accurately and specifically measure differences in viral 
titer.  In this study, we show that the technique can be applied not only to different 
sample types, but shaped into assays with broad applications. 
 The four assays that have been developed are as follows: an individual sample 
EBV viral load assay, an individual sample KSHV viral load assay, a high-throughput 
EBV viral load screen, and a high-throughput KSHV screen.   
 The individual sample EBV assay was developed to detect EBV from a novel 
sample – a patient’s gargle – for the OHARA project.  This kind of sample is easy and 
painless to extract from a patient, and could be used to quickly diagnose oral EBV 
infection.  A diagnostic tool like this would be very useful in medicine as it is quick, 
simple, and cost-effective.  
 The individual sample KSHV viral load assay was developed to evaluate a novel 
mouse model for KSHV.  The assay was used to determine levels of virus in different 
organs.  A model such as this would be very useful in the field of KSHV research, not 
only for studying the molecular dynamics of KSHV, but also for the testing of cures, 
vaccines, etc. 
 The high-throughput EBV viral load screen was developed to screen drug-treated 
lymphoblastoid cell lines (LCL) for EBV reactivation.  In this study, numerous drugs are 
to be tested in different cell lines under different conditions, and the only way to do this is 
with a high-throughput screen.  Quantification is necessary because the 
cell/drug/condition combinations with the highest response will be studied in more detail. 
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 The high-throughput KSHV viral load screen was intended for use in studies of 
KSHV episomal loss. KSHV maintains itself as an episome in the host cell, tethering its 
own circular DNA to the chromosomes of the host via the latent nuclear antigen (LANA).  
In culture, 99% of the infected cells maintain the episome latently, while 1% 
spontaneously loses the episome.  It is this 1% population that is of interest in this study. 
Using quantitative real-time PCR to evaluate viral load of individual samples, we will 
select those with lower viral load to grow up.  This process will continue until a 
population of cells with the lowest possible viral load is isolated.  Once this population 
has been isolated, a number of studies can be done, i.e. deducing which genes are 
controlling the spontaneous shedding of the episome, tumorigenesis studies, and merely a 
statistical analysis of the data collected in this study could shed much light on how 
KSHV maintains itself in the host. Understanding of how the virus is spontaneously lost 
or shed will be a key piece of work that will not only further the knowledge base of 
KSHV, but may provide a pathway for development of a cure. 
 All of these methods were developed for separate purposes, but provide a 
coherent package of viral load analysis of the herpesviruses EBV and KSHV for use in 
future research endeavors.  We will validate these assays using the parameters of 
linearity, precision, dynamic range, sensitivity, and specificity. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
II. METHODS 
 
 Primers. Primers U6, LANA78, K6, ERV3, Hel, EBNA3c and Alu (Table 1) 
were designed from gene sequences found in BLAST database (Figure 1) and purchased 
from MWG Biotech, Inc. (High Point, NC).  Initial concentration of each primer is 
100pmol/!L in 0.1x TE.    
 Positive Control. As a positive control, synthetic oligonucleotide targets were 
designed for U6, LANA78, K6, ERV3, Hel, and EBNA3c.  Each oligonucleotide target 
was designed from the gene sequence in the BLAST database (Figure 1) and purchased 
from MWG Biotech, Inc. (High Point, NC).  Initial concentration of each oligonucleotide 
target is 100pmol/!L.  Each oligonucleotide was diluted from 100 pmol/!L to 1x10
-5
 
pmol/!L.  Using an approximation of Avogadro’s number, 6 x 10
23
 molecules/mol, we 
then conclude that each diluted oligonucleotide target contains 6 x 10
6
 molecules/!L.  In 
the individual sample assays for KSHV and EBV, eight five-fold serial dilutions of this 
oligonucleotide target stock were made in order to construct a standard curve with eight 
positive control samples.  The resulting concentrations and copy numbers are shown in 
Table 2.  For each experiment, the primers used were matched with the oligonucleotide 
targets used.  For each set of primers, an oligonucleotide mix of the previously mentioned 
concentrations was made up.  Because exact copy number can be calculated from QPCR 
results using these oligonucleotide targets, we use these to construct a standard curve for 
our assays, and to calculate exact copy number contained in each sample. 
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QPCR Set-up. For all four assays developed, a ‘master mix’ of primer, 
Lightcycler® 480 SYBR Green I Master (Roche), and sterile water.  SYBR Green I 
Master not only contains all of the components necessary for PCR besides primer, but 
also contains the dye SYBR Green, which will bind to amplified DNA and fluoresce, 
allowing us quantitatively detect levels of fluorescence, and therefore of levels of target 
in the sample being analyzed. For all assays where an NTC (non-template control) was 
used as a negative control, we used sterile H2O. 
Individual sample assay for EBV.  The ‘master mix’ created for this assay utilizes 
the ERV, EBNA, and Hel primers, each at a concentration of 5pmol/!L.  The 
primer:water:SYBR ratio is 1:49:100, and in this case we use 5!L primer, 245!L water, 
and 500!L SYBR for each plate run.  Reactions are pipetted into 96-well plate (Bio-Rad 
Hard Shell 96-well microplate).  After pipetting, each reaction contains 22!L of ‘master 
mix’ and 8!L of sample.  Serial dilutions for the standard curve are also run on the plate.  
Serial dilutions are pipetted in strip tubes (GeneMate 8-strip PCR tube w/o cap, ISC 
Bioexpress) by the robot before transfer to the 96-well plate. 
Individual sample assay for KSHV.  Conditions are the same as above, except the 
primers used are ERV, LANA78, and K6.  ERV and LANA78 are at a concentration of 
5pmol/!L, while K6 is at a concentration of 10pmol/!L. 
High-throughput EBV screen. .  The ‘master mix’ created for this assay utilizes 
the ERV and EBNA primers, each at a concentration of 5pmol/!L.  The 
primer:water:SYBR ratio is 1:24:50, and in this case we use 20!L primer, 480!L water, 
and 100!L SYBR for each plate run.  Reactions are pipetted into a 384-well plate 
(Roche).  After pipetting, each reaction contains 6!L of ‘master mix’ and 4!L of sample. 
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High-throughput KSHV screen. The ‘master mix’ created for this assay utilizes 
the U6 and LANA78 primers, U6 at a concentration of 0.5pmol/!L and LANA78 at a 
concentration of 1pmol/!L.  In this case we use 360!L primer, 324!L water, and 756!L 
SYBR for each plate run.  Reactions are pipetted into a 384-well plate (Roche).  After 
pipetting, each reaction contains 6!L of ‘master mix’ and 4!L of sample. 
Robot and QPCR settings.  The MWG RoboGo! pipetting robot was used to set 
up the reactions. Robot parameters for the individual samples assays for EBV and KSHV 
are shown in Appendix A.  Robot parameters for the high-throughput screens for EBV 
and KSHV are shown in Appendix B.  QPCR for the individual sample assays for EBV 
and KSHV was run in the MJ Research Opticon 2 Continuous Fluorescence Detection 
System. A standard 45-cycle reaction was run with a 5 minute ramp to 95°C, then 15 
seconds at 95°C, then 30 seconds at 62°C.  QPCR for the high-throughput screens for 
EBV and KSHV was run in the Roche Lightcycler® 480 System for 50 cycles (45 of 
them are read), with a pre-amplification ramp of 5 minutes at 50°C, then 5 minutes at 
95°C, and an amplification of 15 seconds at 95°C, then 30 seconds at 62°C, as well as a 
melting curve.  
 Target (DNA) isolation. Samples used in each of the four assays varied greatly in 
nature, so specific DNA isolation protocols were developed for each.   
 Individual sample assay for EBV. Samples from gargle were used in this assay.  
Subjects were given 10mL of sterile PBS in a sterile wide-mouth 50mL conical tube.  
They were asked to gargle for approximately one minute, and then expectorate into the 
tube.  Samples were then combined, and approximately 7mL of the resulting mixture 
transferred to 12mL conical tubes.  Pellets were formed by spinning in a centrifuge at 400 
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x g for 10 minutes.  Most of the supernatant was decanted.  The DNA from the resulting 
pellet was extracted using Promega Wizard® SV Genomic DNA Purification System 
(Table 4) with the protocol for isolating genomic DNA from cells using a 
microcentrifuge.  This was then transferred into Thermo Fischer Scientific Matrix 
Storage Tubes (Hudson, NH) for QPCR use.  In some cases, samples of gargle from 
patients were supplemented with known EBV-positive cells from the cell line B95-8.  
These were simply added to the 12mL conical before pelleting in RPMI media.  Volume 
of RPMI added to total gargle volume was very minimal. 
 Individual sample assay for KSHV.  In this assay, samples from an animal model, 
specifically a mouse, were being used.  DNA was extracted from blood cell pellets, 
spleen cell pellets, and bone marrow cell pellets using the Promega Wizard® SV 
Genomic DNA Purification System (Table 4) with the protocol for isolating genomic 
DNA from cells using a microcentrifuge.  DNA was eluted in 150!L. 
 High-throughput EBV screen.  LCLs are grown up in 384-well plates and variably 
treated with drug.  Identical wells are then combined and transferred to a  96-well plate 
(GeneMate 96-well semi-skirted PCR plate, ISC BioExpress).  Cells are pelleted by 
spinning in a centrifuge.  Supernatant is removed and 100!L of lysis buffer is added.  
Lysis buffer consists of 10mM Tris HCl, pH=8, 2.5mM MgCl2, 1% Igepal, 1% Tween, 
all in sterile water, with 1mg/mL of proteinase K added right before use.  Once the 
sample plate is prepared, the plate is sealed and incubated at 55ºC for 45 minutes in order 
to activate the proteinase K.  The plate is then transferred to a 96-well Eppendorf 
Mastercycler gradient PCR machine and incubated at 99ºC for 15 minutes.  The plate is 
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then spun down for approximately 6 seconds in a centrifuge to ensure lack of air bubbles, 
and to minimize spillage.   
 High-throughput KSHV screen. Cells were grown up in 96-well tissue-culture 
plates in supplemented RPMI 1640 media. When cells reached a concentration of 
approximately 8 x 10
5
 cells/mL, 100!L was transferred to a 96-well plate (GeneMate 96-
well semi-skirted PCR plate, ISC BioExpress).  The plate was sealed and spun in a 
centrifuge at 250 x g for 5 minutes.  Once the cells pelleted, 80!L of media was removed, 
and 100!L of water added to each well.  Cells were pipetted up and down to ensure 
resuspension of the pellet.  The plate was then incubated at 99ºC for 15 minutes in the MJ 
Research Opticon 2 Continuous Fluorescence Detection System. 
 PCR product cloning and sequences. In order to verify that the product being 
amplified in the QPCR reactions was indeed the desired one, PCR product was cloned 
and sequenced.  PCR product was gel-extracted and purified using the Millipore Ultrafree 
DA Kit.  The product was further purified using the Qiagen QIAquick PCR Purification 
Kit.  Insert was prepared with the END-IT™ DNA End-Repair Kit, and vector was 
dephosphorylated using SAP, and both were cut by EcoRV in preparation for ligation.  
The insert was then ligated into a pBluescript II KS (+) vector (Stratagene, La Jolla, CA), 
using T4 DNA Ligase (NEB, Ipswich, MA). The subsequent ligation was heat-shock 
transformed into DH5" competent cells, then plated with IPTG and X-gal.  By using the 
X-gal color assay, we were able to only select the white colonies as those that may 
contain the insert.  Twelve colonies were picked and left to grow up.  A mini-prep of 
these cultures was conducted using the Fermentas GeneJET™ Plasmid Miniprep Kit.  
Resulting DNA was run out on a 1% agarose gel and then sequenced by Eton 
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Biosciences, Inc. (San Diego, CA).  We cloned and sequenced a LANA78 product, and 
two of the resulting clones were positive and once sequenced, matched the BLAST 
database for the LANA78 region.  The agarose gel showing the positive clones can be 
seen in Figure 1. 
 Statistical analysis and computer software.  All statistical analysis and data 
output was calculated using Microsoft® Excel 2004 software (Microsoft).  Program used 
to run Opticon 2 Continuous Fluorescence Detection System is Opticon Monitor v. 
2.02.24 (MJ Research, Inc.). Lightcycler® 480 was run with Lightcycler® 480 software 
release 1.3.0.0705 (Roche).  Program used to run MWG RoboGo! pipetting robot is Robo 
Manager NT v. 4.0.10 (MWG Biotech, Inc.) 
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Table 1. List of primer sequences. 
 
 
 
 
 
F 5'-CTCGCTTCGGCAGCACA-3' 
U6 
R 5'-AACGCTTCACGAATTTGCGT-3' 
F 5'-GGAAGAGCCCATAATCTTGC-3' 
LANA78 
R 5'-GCCTCATACGAACTCCAGGT-3' 
F 5'-CGCCTAATAGCTGCTGCTACGG-3' 
K6 
R 5'-TGCATCAGCTGCCTAACCCAG-3' 
F 5'-CATGGGAAGCAAGGGAACTAATG-3' 
ERV3 
R 5'-CCCAGCGAGCAATACAGAATTT-3' 
F 5'-CCTCTACACCGCCGTCAC-3' 
Hel 
R 5'-ACAAAGCCCAGGATGAACTC-3' 
F 5'-AAGGTGCATTTACCCCACTG-3' 
EBNA3c 
R 5'-AGCAGTAGCTTGGGAACACC-3' 
F 5'-GACCATCCCGGCTAAAACG-3' 
Alu 
R 5'-CGGGTTCACGCCATTCTC-3' 
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Table 2.  Mapping of synthetic oligonucleotide targets and primers onto BLAST 
sequences.  Primers underlined in red, oligonucleotide components in bold. 
 
 
 
Gene Accession # Sequence 
U6 NR_004394 
 
GTGCTCGCTTCGGCAGCACATATACTAAAATTGGAA
CGATACAGAGAAGATTAGCATGGCCCCTGCGCAAGG
ATGACACGCAAATTCGTGAAGCGTTCCATATTTT 
 
LANA78 AF192756 
 
……AGACGGTGGAAGAGCCCATAATCTTGCACGGG
TCGTCATCCGAGGACGAAATGGAAGTGGATTACCCT
GTTGTTAGCACACATGAACAAATTGCCAGTAGCCCAC
CAGGAGATAATACACCAGACGATGACCCACAACCTG
GCCCATCTCGCGAATACCGCTATGTACTCAGAACATC
ACCACCCCACAGACCTGGAGTTCGTATGAGGCGCG
TTCCA…… 
 
K6 U74585 
 
……ACTCGTGTCGTACACGCCTAATAGCTGCTGCTA
CGGGTTCCAGCAGCACCCACCGCCCGTCCAAATTCT
AAAAGAGTGGTATCCCACGTCCCCAGCGTGCCCAAAA
CCCGGAGTTATTTTGCTGACCAAGCGAGGGCGTCAGA
TCTGCGCAGACCCTTCCAAAAACTGGGTTAGGCAGC
TGATGCAGCGGC…… 
 
ERV3 NM_001007253 
 
……ACCAATGGCCATGGGAAGCAAGGGAACTAATG
CCCCAAGATAATTTCACACTAACCGCCTCTTCCCTCG
AACCTGCACCATCAAGTCAGAGCATCTGGTTCTTAAA
AACCTCCATTATTGGAAAATTCTGTATTGCTCGCTG
GGGAAAGGCCT …… 
 
Hel V01555 
 
……GTTGGTGCCACAAAGCCCAGGATGAACTCGTCT
GCATAAGCCCAGGTCAGTCCTAGGTCAGCGGCCGCG
TGTAGGAGAACCCGGGTGACGGCGGTGTAGAGGCC
CCCGAG…… 
 
EBNA3c V01555 
 
……TACAGTCAAGGTGCATTTACCCCACTGGACATT
AATGCCACCACGCCAAAAAGGCCTCGAGTAGAAGAA
AGTTCTCACGGACCTGCCCGGTGTTCCCAAGCTACT
GCTAGGACGCG…… 
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Table 3. Oligonucleotide target dilution series. From initial stock concentration of 6 
x 10
6
 molecules/!L, 8 five-fold dilutions made. 5!L used in the QPCR reaction. 
 
 
molecules/!L copy number 
1200000 6000000 
240000 1200000 
48000 240000 
9600 48000 
1920 9600 
384 1920 
76.8 384 
15.36 76.8 
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Table 4. Theoretical amplification introduced by Promega Wizard® SV Genomic 
DNA Purification System (assumes 1 copy of EBV/KSHV genome/!L input or 10
3
 
copies/mL)  
 
 
 
 
Step: Promega 
input volume 600 µL  
elution volume 100 µL  
amplification factor 6x 
copies/µL  6 
  
Standard QPCR   
maximal replicates 11+1 
input volume 8 µL  
final volume 30 µL  
amplification factor 0.27x 
copies/well 48 
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Figure 1. 1% Agarose gel of cloned LANA78 PCR products.  Lanes 8 
and 12 yielded clones that upon sequencing were found to match the 
BLAST alignment for LANA78 (See Table 2).  Lane 8 represents a 
head-to-head trimer of LANA78, Lane 12 represents a head-to-head 
dimer of LANA78, and Lane 4 represents an irrelevant product.  
 
 
 
 
 
III. RESULTS 
 Differences between target DNA and positive control established.  In order to 
assure that there is no cross-contamination during robot pipetting or sample preparation, a 
precaution was built into the assays.  As mentioned previously, for each primer set there 
is a synthetic oligonucleotide target that can behave as a positive control for the primers 
(Table 2).  These oligonucleotides were designed so that their sequence is significantly 
shorter than that of the PCR product from sample DNA, i.e. they are shorter than the full-
length product.  This allows us to perform a qualitative control on our results by 
visualizing the PCR products with agarose gel electrophoresis.  We expect the synthetic 
oligonucleotide to run more quickly and appear further down the gel than the full-length 
amplicon. It is clear that there is a detectable difference between the synthetic 
oligonucleotide target used for the standard curve for both the individual sample assay for 
KSHV (Figure 2) and the individual sample assay for EBV (Figures 3A and B). We can 
also see in Figs. 2 and 3 that it is established that there is no cross-contamination during 
any point of the assay – we do not see the shorter amplicon from the standard in the wells 
of the sample. 
 Linearity. In order to validate an assay, we need to establish that the standard 
curve of the assay approximates a straight line (9).  The linear standard curve also defines 
the linear range of the assay.  If values from various samples rise above or below the 
linear range, we cannot make conclusions about the viral load contained in that sample 
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from the standard curve.  We can see that for both the EBV assay (Figure 4) and the 
KSHV assay (Figure 5), the assay is linear as reflected by the R
2
 value. 
 For the EBV assay, the ERV, EBNA3c and Hel primers have R
2
 values of 0.984, 
0.9905, and 0.9838 respectively using n=8 dilution points.  
 For the KSHV assay, the ERV, K6 and LANA78 primers have R
2
 values of 
0.9958, 0.9936, and 0.9863 respectively using n=8 dilution points.  
 Precision. In order for the assays to be functional, a certain level of precision 
needs to be obtained for each primer set used.  Precision requires that the assay achieve 
similar viral quantification values regardless of external variables for same samples.  
Precision is quantified by determining the change in viral load that is statistically 
significant.  DHHS guidelines state that in a valid assay, a viral load change of 3-fold (0.5 
log 10) is the minimum change that is considered significant (9).  Here we will show that 
we have achieved this for the EBV and the KSHV assay.  We used 2-fold increases in 
cell number ranging from 1000 to 32000 cells.  The data combine a variation of sample 
preparation and QPCR since the number of cells indicated for each sample represents to 
number of cells input into the DNA purification system. 
 For the EBV assay, we have attained a high level of precision.  From Figure 6, we 
can see that for the three primers – ERV (Fig. 6A), EBNA3c (Fig. 6B) and Hel (Fig. 6C), 
we are able to detect a 2-fold difference with statistical significance – more precise than 
the DHHS requirement of 3-fold detectable difference.  This difference was detectable 
through the entire range of target cell count that we tested – 1000 cells to 32000 cells.  
This validates the use of these three primers in the EBV assay as precise. Regression 
analysis for this data can be seen in Table 5. 
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 For the KSHV assay, we see in Figure 7A that the ERV primer can accurately 
detect 2-fold differences between 1000 and 16000 cells with statistical significance.  
Once the cell count, and therefore amount of virus being measured, reaches this 
threshold, we cannot ascertain the 2-fold difference with statistical significance.  
Therefore to a cell count of 16000 we have achieved a precision of a 2-fold change – 
better than the DHHS minimum of 3-fold.  Figure 7B shows the data for the K6 primer.  
We see that this is far less able to accurately detect the differences in target.  We cannot 
accurately detect 2-fold differences for K6, but a 4-fold difference in target is statistically 
significant.  This is greater than the 3-fold difference prescribed by DHHS, so we cannot 
use the K6 primer in a validated assay.  However, in Figure 7C we see that for the 
LANA78 primer, we have achieved a precise result.  A two-fold difference in target cell 
number can be detected with statistical significance across the whole range tested, from 
1000 to 32000 cells, exceeding DHHS standards.  Regression analysis for this data can be 
seen in Table 6. 
 Dynamic Range.  The data from Figs. 6 and 7 not only demonstrates the 
precision of the assay, it quantifies the dynamic range of the assay.  Dynamic range is 
defined by the quantitative range over which the assay can reliably report results (9).  For 
both the EBV and KSHV assays, we tested a range of 1000 to 32000 EBV+ or KSHV+ 
cells with 2-fold differences.   
 For the EBV assay, all three primers report statistically significant differences 
between each of the 2-fold differences, allowing us to say these differences are precise.  
Therefore the dynamic range of the EBV assay is 1000 to 32000 cells.  However, the 
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upper limit of this assay is still unexplored, and it is possible that the dynamic range is in 
fact greater than 32000 cells. 
 For the KSHV assay, the LANA78 primer was able to detect the full range tested 
– from 1000 cells to 32000 cells.  ERV was able to detect up to 16000.  However, K6 was 
unable to achieve this level of precision.  Because LANA78 and K6 are both measures 
for KSHV copy number, we can change the assay from using three primers to two – only 
ERV and LANA78, to achieve a dynamic range of 1000 to 16000 cells. 
 Sensitivity.  The sensitivity of an assay is measured by the Limit of Detection 
(LoD), which is the minimal number of cells, i.e. the lowest viral load level, that are 
distinguishable from the negative control (NTC) (9).   
 In Figure 8, we calculated the sensitivity of the EBV assay for the three primers 
ERV (Fig. 8A), EBNA (Fig. 8B) and Hel (Fig. 8C).  We can see for the ERV primer, that 
we could not distinguish between 100 cells and the NTC, however there was a 
statistically significant difference between 1000 cells and the NTC, establishing 1000 
cells as our LoD for the ERV primer (Fig. 8A).  The EBNA primer’s results are more 
complex.  We see that for 100 cells, we have two different results.  For the 100a target 
cell sample, we see that there is a statistical significance from the NTC, however for the 
100b target cell sample, we cannot distinguish between it and the NTC.  Because one of 
the supposedly identical samples was not different from the negative control, we cannot 
use 100 cells as our LoD for the EBNA primer, however 1000 cells is clearly statistically 
distinguishable from the NTC, therefore our EBNA LoD is also 1000 cells (Fig. 8B).  
The Hel primer yields similar results.  There is no statistical significance between 100 
cells and the NTC, but the difference between 1000 cells and the NTC is well established 
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(Fig. 8C).  Therefore we can conclude that for the entire EBV assay, our LoD is 1000 
cells.   
 For the KSHV assay, we calculated the sensitivity of the three primers ERV, K6 
and LANA78 (Figure 9).  For ERV, we see that both 100a and 100b cell samples show a 
statistically significant difference when compared to the NTC, therefore we can 
confidently say that the LoD for ERV in this assay is 100 cells (Fig. 9A).  However, for 
the K6 primer, we see that the assay is only sensitive to 10000 cells, and anything less 
than that does not differ statistically from the NTC, giving this primer an LoD of 10000 
cells (Fig. 9B).  For LANA78 we have a result similar to ERV in that the LoD is 100 
cells (Fig. 9C).  We see that for both 100a and 100b target cell samples, they are vastly 
statistically significantly different from the NTC. 
 Specificity.  The specificity of an assay is determined by its ability to only assess 
our target, i.e. if the assay is specific, it will have a low rate of false-positives (9).  With 
our assays, to look at specificity we can examine the NTCs for both the EBV and KSHV 
assays.  We can confirm that our assay is specific in two ways – qualitative and 
quantitative.  By examining Fig. 2 for the KSHV assay and Fig. 3 for the EBV assay, we 
can qualitatively see from the agarose gel electrophoresis that the NTC lanes are empty – 
no product was amplified, whereas product was amplified in both the sample and positive 
control lanes.  Visually, we can confirm no false positives.  However it is important to 
ascertain quantitatively that there were no false positives.  We can see by looking at Fig. 
8 for the EBV assay, that the values for the NTC were zero for the ERV, EBNA and Hel 
primers – meaning that no product was seen even by quantitative analysis in the whole 
assay.  This is confirmed not once, but twice for each primer set as two different NTCs 
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were run.  In Fig. 9 we see the same result for all the primers – ERV, K6, and LANA78.   
None of the NTCs yielded any product.  This establishes that our assays have a high 
specificity. 
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Figure 2. Establishment of differences between synthetic oligonucleotide 
positive control and full-length sample amplicon in the individual 
sample KSHV assay. Samples Thy1A and Thy3 356 are both thymus 
samples from the mouse model.  Sp3 350 is a spleen sample.  Shows the 
gel resulting from the samples primed by LANA78.  Positive control 
lanes clearly run longer than sample lanes, and there is clearly no cross-
contamination as the NTC does not show either the faster or slower 
band.
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Figure 3. Establishment of differences between synthetic oligonucleotide 
positive control and full-length sample amplicon in the individual 
sample EBV assay.  EBV + sample in this case was a subject sample 
(DNA from gargle pellet) supplemented with 10
3
 B95-8 cells. (A) Shows 
the gel resulting from the samples primed by ERV.  Positive control 
lanes clearly run longer than EBV+ sample lanes, and there is clearly no 
cross-contamination as the NTC does not show either the faster or 
slower band.  (B) Same as Figure 3A, except primed by EBNA3c. 
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R2= 0.984 
R2= 0.9905 
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Figure 4. Establishing the linearity of the assay for EBV.  Using the 
synthetic oligonucleotide positive controls, we established a linear 
standard curve.  (A) For the ERV primer, the calculated R
2
 value is 
0.984. (B) For the EBNA primer, the calculated R
2
 value is 0.9905. (C) 
For the Hel primer, the calculated R
2
 value is 0.9838.  These data 
establish the linearity of our assay in the range of our standards.
R2= 0.9838 
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R2= 0.9958 
R2= 0.9936 
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Figure 5. Establishing the linearity of the assay for KSHV.  Using the 
synthetic oligonucleotide positive controls, we established a linear 
standard curve.  (A) For the ERV primer, the calculated R
2
 value is 
0.9958.  (B) For the K6 primer, the calculated R
2
 value is 0.9936. (C) For 
the LANA78 primer, the calculated R
2
 value is 0.9863. These data 
establish the linearity of our assay in the range of our standards. 
 
R2= 0.9863 
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Figure 6.  Quantification of the level of precision in the EBV assay.  In 
this experiment, we quantified the viral load of samples with a 2-fold 
difference in EBV+ cell count (in this case BC1 cells), run in triplicate.  
Our range was from 1000 cells to 32000 cells.  We ascertained whether 
the assay was capable of detecting this 2-fold difference using the 
primers (A) ERV (B) EBNA and (C) Hel.   
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Table 5. Regression analysis for the quantification of precision (Fig. 6) in the EBV 
assay. 
 
 
 
 
 R2 Slope 
ERV 0.9785 4.9498 
EBNA 0.9891 17.471 
Hel 0.9755 18.889 
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Figure 7.  Quantification of the level of precision in the KSHV assay.  In 
this experiment, we quantified the viral load of samples with a 2-fold 
difference in KSHV+ cell count (in this case BCBL-1 cells), run in 
triplicate.  Our range was from 1000 cells to 32000 cells.  We 
ascertained whether the assay was capable of detecting this 2-fold 
difference using the primers (A) ERV (B) K6 and (C) LANA78.   
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Table 6. Regression analysis for the quantification of precision (Fig. 7) in the KSHV 
assay. 
 
 
 
 
 R2 Slope 
ERV 0.6327 0.0254 
K6 0.8045 0.0053 
LANA78 0.9773 3.2399 
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Figure 8. Quantifying sensitivity for the EBV assay. The copy number 
found in samples for 100000, 1000, 100 and no EBV+ BC1 cells as 
assayed by the primers (A) ERV, (B) EBNA and (C) Hel.  Each sample 
was made in duplicate, i.e. 10000a, 10000b, and each was run in 
triplicate.
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Figure 9. Quantifying sensitivity for the KSHV assay. The copy number 
found in samples for 100000, 1000, 100 and no KSHV+ BCBL-1 cells as 
assayed by the primers (A) ERV, (B) K6 and (C) LANA78.  Each 
sample was made in duplicate, i.e. 10000a, 10000b, and each was run in 
triplicate.
  
 
 
 
IV. DISCUSSION 
 Establishing a validated assay.  In this study, we established assays for viral 
load of KSHV and EBV.  Constructing easy-to-use and low-cost assays that are 
quantitative such as these  to use as tools in the laboratory is very useful, not only for the 
experiment they were designed for, but because they can be applied to a broad range of 
projects.  In these assays, various kinds of samples are used, for purposes ranging from 
basic research to medical diagnostics.   
 We validated the assays using the parameters of linearity, precision, dynamic 
range, sensitivity, and specificity.  For the EBV assay, we validated the primers ERV3, 
EBNA3c and Hel, ERV3 primes for a human endogenous retroviral sequence, and is 
therefore a marker for cellular, not viral, load (33).  ERV3 is a single-copy gene, and 
therefore very meaningful to our assay, because data from the ERV3 primer will more 
accurately reflect the actual viral load.  EBNA3c primes for the EBV nuclear antigen 3c, 
therefore it is a marker for viral load.  Hel is also a marker for an open reading frame 
(ORF) in EBV.  For the KSHV assay, we attempted to validate the primers ERV3, K6 
and LANA78.  K6 is a primer for the K6 ORF of KSHV, making it a viral marker.  
LANA78 is another viral primer for the latent nuclear antigen of KSHV.   
 The EBV assay was validated to all of the parameters.  The linearity of the assay 
was established, as the construct standard curves of each primer had R
2 
values between 
.9838 and .9905, meaning that between 98.38% and 99.05% of the data are accounted for 
by assuming a linear model (Fig. 4).  This is a very high number and not only establishes 
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our standard curve, but shows that the pipetting in our assay is accurate, and we can 
confidently use this curve to calculate values for our sample data.  The EBV assay also 
held up under scrutiny when we examined it’s precision.  For all the three primers – 
ERV3, EBNA3c, and Hel, we are able to, with statistical significance, detect a 2-fold 
difference (Fig. 6). This is very good, because the DHHS requirement for a validated 
assay is that a 3-fold difference be the minimum detectable difference.  With a 2-fold 
difference validated for these primers, we can be confident applying in this assay in the 
dynamic range of 1000 to 32000 cells.  We validated this assay on EBV latently infected 
BC1 cells, since the two envisioned applications are to measure intracellular viral load.   
These cells carry more than one viral genome copy per cell, but less than ten. An 
extension of this work will be to use calibrated free EBV virus such as available from 
Advanced Biotechnologies incorporated (cat#10-115-000). Although this is quite a 
precise reading, in the future we would want to expand the dynamic range of the assay 
and test more intervals of target cell number greater than 320000.  For all the of the EBV 
primers we found that the LoD was 1000 cells – any less than this and we could not 
detect a difference from the NTC with any statistical significance, therefore we can say 
that 1000 cells is the bottom end of the sensitivity for this assay (Fig.8).  This assay has 
also proven to be highly specific, priming only positive control and sample, yielding no 
false positive NTCs.  We can see this qualitatively by gel electrophoresis in Fig. 3 and 
quantitatively by QPCR in Fig. 8.  From these data, we see that the EBV assay for the 
primers ERV3, EBNA3c and Hel was validated and is ready to be applied. 
 The KSHV assay was also successfully validated.  The linearity of this assay was 
also very high, with the R
2 
values for our oligonucleotide standards falling between 
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0.9863 and 0.9958, meaning that between 98.63% and 99.58% of the data fit to a linear 
model (Fig. 5).  The linearity results for both of the assays are highly robust, establishing 
that both the KSHV and EBV assays have strong linearity within the range of the positive 
control standard, and any we can be confident about making calculations of copy number, 
etc. for a result that falls in this range when we look at non-control samples.  When we 
examined the precision of the KSHV assay, it became apparent that the K6 primer should 
not be used for this purpose.  While the ERV3 and LANA78 primers were both able to 
detect a two-fold difference in target cell, K6 was only able to detect a 4-fold difference 
(Fig. 7).  We also saw that by quantifying the sensitivity of the assay, K6 would not be a 
good primer to use for sample analysis.  While ERV3 and LANA78 were able to detect 
100 cells with statistical significance, K6 was only able to detect 10000, which is not 
sensitive enough for our purposes (Fig. 9).  Therefore, if we only use ERV3 and 
LANA78 in our assay, it would have an LoD of 100 cells. Like the EBV assay, we can 
also say that the KSHV assay is highly specific, as we do not see false positives 
qualitatively on a gel (Fig. 2) or quantitatively by QPCR (Fig. 9).  From these data, we 
can say that we have established a validated KSHV assay for the primers ERV3 and 
LANA78. We validated this assay on KSHV latently infected BCBL-1 cells, since the 
two envisioned applications are to measure intracellular viral load.   These cells carry 
more than one viral genome copy per cell, but less than twenty. An extension of this work 
will be to use calibrated free KSHV virus. This will need to be generated in the future and 
particle counts will need to be obtained by electron microscopy 
 Limitations.  Although from the data both the EBV and KSHV assay appear 
robust, there are limitations to both assays in that the number of samples tested is low.  In 
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order to further validate the assay, we should look at the parameter of accuracy, and try to 
repeat the results we found above multiple times with several different runs, different 
samples, on different days.  This would also allow us to establish inter-plate variation, 
which would quantify our inter-assay accuracy.  Broadening the dynamic range of the 
assay would also further its usefulness to the field.  Further testing the precision of the 
assay with higher 2-fold increases in cell amount would accomplish this. 
 Assay vs. screen. By validating the EBV and KSHV assays in this study, we are 
in turn validating the EBV and KSHV screens that have previously been discussed.  In 
order to establish a correlation between fluorescence and copy number, etc., one needs to 
establish a base line, in this case our standard curve with the synthetic oligonucleotides.  
Once this standard has been established and shown to be repeatable within a narrow 
range, one can apply the statistics from this assay to a screen that employs the same 
methodology.  A screen does not include a standard curve, but typically marks results as 
either ‘+’ or ‘-‘, having or not having the gene of interest.  In this case, since we are 
validating an assay with the same techniques, we can do a quantitative screen and show 
not only which samples we test have the virus, but also we can assess the viral load. 
 Applications.  The assays and screens developed here were each developed for a 
singular, unique purpose.  The individual sample EBV viral load assay was developed as 
part of the OHARA project to quantify viral load from a gargle sample from a patient – 
an easy, painless way to diagnose oral levels of virus.  The individual sample KSHV viral 
load assay was developed to test whether or not a novel mouse model for KSHV was 
indeed a valid one – whether its organs were expressing the virus or not, and if so, to 
what levels.  The high-throughput EBV viral load screen will be used to assess drug 
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response in LCLs to a large variety of drugs and different cell lines so that those with the 
greatest response can be selected and studied further.  The high-throughput KSHV viral 
load screen will be used to study mechanisms of loss and/or shedding of the KSHV 
episome in B-cells.   
 All of these applications are extremely worthy, but if we step back and look at the 
collection of assays developed for very different purposes, we can identify that we have 
developed a package of assays and screens to assess the levels of two different gamma 
herpesviruses – EBV and KSHV.  This package can be useful to the field in many 
different ways, and can possibly be expanded in the future to include other herpesviruses. 
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APPENDIX A. MWG RoboGo! parameters for individual sample assays. 
 
TASK: 3 primers for 8 different samples (each combined with 2x 
SYBR) into 96 well plate at 30 µl total reaction volume  
OPERATION PARAMETER SETTING (100 µL 
SYRINGE) 
General Prime 4 µl 
 Waste (primer ; sample) 2 µl 
 Airgap to System 10 µl 
 Separation airgap 0 µl 
 Transport airgap 2 µl 
 Spit airgap before dispense Enabled 
 Pick airgap when changing slot Disabled 
 Spit system airgap at waste Enabled 
Aspiration Speed 70 µl/s 
 Pre-delay, post-delay 200 ms, 500 ms 
 Liquid level sensing  Disabled 
 Tracking and submerge Enabled, 15 steps 
 Retract speed 1500 steps/s 
Dispense Speed 120 µl/s 
 Pre-delay, post-delay 500 ms, 500 ms 
 Liquid level sensing Disabled 
 Tracking and dispense height 
(dry ; wet) 
Enabled, 15 steps 
 Retract-speed (primer ; sample) 500 steps/s 
Wash/ flush Repeat 4 times 
 Flush syringe at waste pos.; 
wipe 
Enabled; Disabled 
 Peripump time 1000 ms 
 Detergent time 0 
 System airgap after flush 0 µl 
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APPENDIX B. MWG RoboGo! parameters for high-throughput screens. 
 
TASK: 2 primers for 96 different samples (each combined with 2x 
SYBR) into 384 well plate at 10 µl total reaction volume  
OPERATION PARAMETER SETTING (100 µL 
SYRINGE) 
General Prime 2 µl 
 Waste (primer ; sample) 2 µl 
 Airgap to System 2 µl 
 Separation airgap 0 µl 
 Transport airgap 2 µl 
 Spit airgap before dispense Enabled 
 Pick airgap when changing slot Disabled 
 Spit system airgap at waste Enabled 
Aspiration Speed 100 µl/s 
 Pre-delay, post-delay 100 ms, 200 ms 
 Liquid level sensing  Enabled 
 Tracking and submerge Enabled, 15 steps 
 Retract speed 1000 steps/s 
Dispense Speed 200 µl/s 
 Pre-delay, post-delay 100 ms, 500 ms 
 Liquid level sensing Disabled 
 Tracking and dispense height 
(dry ; wet) 
Enabled, 15 steps 
 Retract-speed (primer ; sample) 350 steps/s 
Wash/ flush Repeat 1 times 
 Flush syringe at waste pos.; 
wipe 
Enabled; Disabled 
 Peripump time 1000 ms 
 Detergent time 0 
 System airgap after flush 5 µl 
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